<DOC>
	<DOCNO>NCT00219245</DOCNO>
	<brief_summary>Patients complete 12-week double blind protocol may enter 26-week , open-label extension . This extension give patient complete study opportunity receive treatment open-label rivastigmine 3-12 mg/day evaluation cognitive deficit relate traumatic brain injury . This extension enable evaluation patient , well analyse conduct examine response treatment original drug placebo group .</brief_summary>
	<brief_title>An Extension Study Evaluating Efficacy Safety Rivastigmine Patients With Traumatic Brain Injury ( TBI ) With Persistent Cognitive Deficits</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Have deficit area attention and/or memory . Have current cognitive deficit present time injury , persistent , deem result brain injury ; Be least 12 month post brain injury ; A history major brain surgery ; A penetrating brain injury ( e.g. , gun shot wound ) ; A current diagnosis epilepsy ; Had one seizure past year ( patient single seizure within year postinjury consider case case basis ) ; Previous exposure rivastigmine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Traumatic brain injury , head trauma , rivastigmine , cognitive deficit</keyword>
</DOC>